Savvy Advisors Boosts AbbVie Stake by 22%

Investment firm increases holdings in pharmaceutical giant during Q4 2025

Apr. 5, 2026 at 9:50am

Got story updates? Submit your updates here. ›

Savvy Advisors Inc. increased its stake in AbbVie Inc. (NYSE: ABBV) by 22.2% during the fourth quarter of 2025, according to a recent SEC filing. The investment firm now owns 36,568 shares of the pharmaceutical company's stock, valued at $8.355 million.

Why it matters

This transaction highlights the continued investor interest in AbbVie, a major player in the biopharmaceutical industry. The stock's performance and growth prospects make it an attractive target for institutional investors like Savvy Advisors.

The details

Savvy Advisors added 6,646 shares of AbbVie to its portfolio during the fourth quarter, bringing its total holdings to 36,568 shares. The firm's investment in AbbVie is now valued at $8.355 million, up from $6.84 million at the end of the previous quarter.

  • Savvy Advisors increased its AbbVie stake during the fourth quarter of 2025.
  • The firm's latest SEC filing was made on April 5, 2026.

The players

Savvy Advisors Inc.

An investment management firm that has increased its holdings in the pharmaceutical company AbbVie.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Savvy Advisors' increased stake in AbbVie reflects the pharmaceutical company's continued appeal to institutional investors. As AbbVie navigates the competitive biopharmaceutical landscape, its stock performance and growth potential make it a sought-after investment target.